醒脑静联合依达拉奉治疗重症脑梗死临床研究

Clinical study of Xingnaojing combined with edaravone in the treatment of severe cerebral infarction

目的对醒脑静联合依达拉奉治疗重症脑梗死的临床疗效展开研究。方法 80例重症脑梗死患者作为研究对象,按随机数字表法分成探究组与对照组,各40例。对照组患者采用单一的醒脑静进行治疗,探究组患者在采用醒脑静治疗的同时联合依达拉奉进行治疗。对比两组患者的临床治疗效果。结果探究组患者治疗总有效率95.00%高于对照组67.50%,差异具有统计学意义(P<0.05)。治疗前,两组患者的神经功能缺损评分及生活能力评分对比,差异均无统计学意义(P>0.05);治疗后,两组患者的神经功能缺损评分及生活能力评分均较本组治疗前改善,且探究组改善程度优于对照组,差异均具有统计学意义(P<0.05)。结论针对重症脑梗死患者给予醒脑静联合依达拉奉进行治疗能有效改善患者病情症状,降低安全风险,疗效可靠。

Objective To study the clinical efficacy of Xingnaojing combined with edaravone in the treatment of severe cerebral infarction. Methods A total of 80 severe cerebral infarction patients as study subjects were divided by random number table method into research group and control group, with 40 cases in each group. The control group was treated with Xingnaojing, and the research group was treated with Xingnaojing and edaravone. Clinical treatment effect in two groups was compared. Results The research group had higher total treatment effective rate as 95.00% than 67.50% in the control group, and the difference had statistical significance （P〈0.05）. Before treatment, both groups had no statistically significant difference in neurological impairment score and life ability score （P〉0.05）. After treatment, both groups had better neurological impairment score and life ability score than before treatment, and the research group had better improvement degree than the control group. Their difference had statistical significance （P〈0.05）. Conclusion Combination of Xingnaojing and edaravone shows reliable efficacy for patients with severe cerebral infarction, and it can effectively improve their symptoms and reduce safety risks.